Skip to main content

Alnylam Receives $10M from Takeda for Tech Transfer

Premium

Alnylam Pharmaceuticals said this week that it has received a $10 million payment from partner Takeda Pharmaceutical related to an alliance the companies formed in 2008.

According to Alnylam, the payment is specifically tied to the achievement of undisclosed objectives in the transfer of its platform technology, including documents, materials, and know-how to the Japanese firm for the development of RNAi-based therapeutics.

In mid-2008, Alnylam announced that it had signed a deal giving Takeda worldwide, non-exclusive access to its RNAi intellectual property and technology to help develop drugs for cancer and metabolic diseases (GSN 5/29/2008). In exchange, Alnylam received $150 million upfront, and was eligible to receive $50 million in technology-transfer payments, and up to $171 million in development and commercial milestones, as well as royalties.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.